Basic drug bidding Anhui model Strong earthquake Chinese Medicine Association opposes only low price

Absrtact: Since the publication of the "Anhui model" in July this year, the industry has been fiercely opposed to the sharp decline in drug prices.　　The Chinese Association of Chinese Medicine has recently organized a seminar in Beijing to oppose the "Anhui model", which is taken only at a low price, given that the pharmaceutical companies around the world are constantly talking about the issue of basic drug bidding in Anhui province.　　"2010 Anhui Province, the list of successful varieties of basic drugs," once announced, the domestic mainstream Chinese medicine enterprises can not sit. Since the publication of the "Anhui model" in July this year, the industry has been fiercely opposed to the sharp decline in drug prices.　　The Chinese Association of Chinese Medicine has recently organized a seminar in Beijing to oppose the "Anhui model", which is taken only at a low price, given that the pharmaceutical companies around the world are constantly talking about the issue of basic drug bidding in Anhui province. As the leading group of drug bidding and procurement work in Anhui medical institutions suspended the old version of the province's tender proposal for basic drugs, it was openly stated that the moratorium was intended to be consistent with the spirit of the national new procurement document for basic medicines, and that the "double envelope" of the technical tender and the post　　System has been incorporated into the research field of relevant policy development departments, coupled with the "Anhui Model" formally adopted the "double envelope" system, the series of signs, so many in Anhui Province, the failure of the basic drugs bidding enterprises are very uneasy, they worry about the country's new procurement of basic drugs bidding documents will promote the "Anhui model." "This quote most enterprises do not come out" the "two envelopes" of the basic drug bidding in Anhui Province, that is to participate in the bidding of enterprises to prepare technical standard and business Standard two envelopes, technical standards, including the size of enterprises, supply capacity, quality control capacity, and many other criteria,　　As long as the pharmaceutical companies want to participate in the province's basic drug bidding must first pass the technical standard, in the business bid selection process only consider price factors, select the lowest price of several varieties won the bid.　　In addition, Anhui Province in order to be able to lower prices, but also adopted the "one factory one product one regulation" model, the government to replace the market with administrative means of competition, a province's share in exchange for low prices.　　In this respect, north China's two largest state-owned pharmaceutical groups in charge of the sales department told reporters that Anhui is the first implementation of the "double envelope" system of the province, the practice is to lower prices. "1g specifications of the injection of Qusong sodium, we quote 1.80 Yuan, but a company in Shandong, the final bid for 1.25 yuan, this is simply the price of cabbage, 1.25 of the price of most enterprises will certainly not produce, even if produced, there is no profit."　　"A veteran state-owned pharmaceutical Enterprise Marketing department deputy general manager as told reporters. "But the excessive pursuit of low prices, to the common People's drug safety where?" We have reported the lowest prices, but other companies are getting lower, and we don't know how they are produced. According to common sense, large enterprises because of the scale effect, the cost is usually lower than small enterprises. The ' Anhui model ' excessively pursues the low price, the one-sided policy view which is guided by the price has made our big enterprise ' squeeze ' very painful. According to the South reporters understand that in Anhui Province, the basic drug tender, the domestic stone pharmaceutical Group,Guangzhou Pharmaceutical, Baiyun Mountain Pharmaceutical, Harbin Pharmaceutical group, north China Pharmaceutical and so on because the competitor quoted too low, the winning rate is not high.　　Whether the national promotion is still unknown South reporters October 12 from the Chinese Pharmaceutical Enterprise Management Association president Yu learned that the state of the new procurement of basic drugs bidding documents have been basically completed, most likely in the recent official release. Yu said: "The basic drug bidding ' Anhui model ' will not be promoted, it is still difficult to say, but should not be promoted." "He believes that the double envelope is a pattern, there is no substantive meaning, the essence is the only low price is taken."　　This model will produce a very poor result: the price is too low, will eventually hurt the interests of the people. Yu also pointed out that "Anhui model" in several points do not conform to the law, he said, "one factory one product one regulation" practice, once implemented, there will be a large number of enterprises closed down, because this practice only individual enterprises can be a foothold, this is obviously an administrative order. Secondly, the "Anhui model" stipulated in the Contract for drug purchase and sale, is to sign the contract with the tender, not the buyer and seller. Because the tendering office cannot undertake the civil action responsibility, obviously is inconsistent with the company law's request.　　Is I. In fact, the practice of Anhui is not a local protectionism, because the successful bidder is also small enterprises in the field, the number of local drug companies is not particularly large. But because the successful bidder are small enterprises, they will find ways to cut corners. The end result is a lower price, but also a drop in quality.　　Said to the reporter in Ming de.　　The pros and cons of the model argue that medical analysts say if the "Anhui model" in the country to promote, will have a profound impact on general drug prices downward, even if not promoted, because each province will be more than the surrounding provinces, the price of the drug, will continue to lower the prices of ordinary drugs, but also to other provinces, the basic drug tender impact. Yu told reporters that the "Anhui model" is still limited to Anhui, other provinces have not copied the signs, but now all over the hope that the use of administrative methods to control the price of the practice.　　For example, Guangdong Province, "control the highest retail prices, control the actual supply price, control the circulation rate" of the 13 control practices. Shong, president of Kyushu Group, said throughout the process of Anhui model, it has achieved a breakthrough in some areas, for example, "double envelope" in the true sense of the "Quality First" and "reasonable price" of the combination; "One factory one product one regulation" This method of price linkage,　　The strange phenomenon that solved more than 10 years drug to win the bid but did not sell, the bidding enterprises can decide the bidding price according to the dosage of a province. In addition, a variety of medical institutions only a choice of policy design, so that through the rebate competition to promote the way the loss of the soil, will help curb the spread of commercial bribery in primary health care institutions.　　Shong said that after the Anhui model came out, more focused procurement of basic drugs at the provincial level of tender exploration will continue to deepen, the state of the basic drug procurement mechanism of the work of the Code will be published in due course. Related news Chinese Medicine high quality price and base medicine limit two politicalThe paradox of the old drug-enterprise dilemma with the local procurement of essential drugs into the substantive implementation phase, the original quality of good prices but shortlisted for the basic drugs of Chinese patent medicine enterprises, the current situation in the provincial bidding is embarrassing.　　Canton Pharmaceutical Pangao Pharmaceutical Co., Ltd. chairman Wei to the South reporters, because the quality of proprietary Chinese medicine and basic drug pricing policy is the national Development and Reform Commission, the National Development and Reform Commission should start to deal with the contradiction between high quality and price. Wei that there is a difference between proprietary Chinese medicine and chemical medicine, the same variety of proprietary Chinese medicine, because the lack of quantitative quality standards, often there will be greater differences in quality, it is because of this, the National Development and Reform Commission earlier specifically for proprietary Chinese medicine set up a high quality price policy.　　But some of the best quality drugs in the shortlist after the basic drugs, in fact, has not been able to enjoy the high quality and price policy support: Although the NDRC did not abolish high quality price policy, but due to the introduction of the basic drug price, the current provincial basic drug bidding and price-oriented, the actual implementation of the basic drug price. "To Pangao Shedan Chuanbei Liquid As an example, the development and Reform Commission set a high quality price of 1.95 yuan per, but because it is the basic drugs, the current ceiling price has been set at 1 yuan per." And our original factory price in 1.2~1.3 yuan each. With such a limit, the more we produce, the more we lose.　　"Wei said.　　According to South reporters understand that, because in many provinces, especially in Anhui and Shanghai Minhang Basic drugs in the tender, and Pangao like the old state-owned pharmaceutical companies are in a dilemma: either the bid low price, shoddy to reduce costs, or give up the bid, lose the market. Some people in the industry told reporters that, in fact, in addition to some of the high prices of varieties, the current substantial part of the price of essential drugs is not a virtual high, but a virtual low. "For some of the relatively low prices of proprietary Chinese medicines, the NDRC should not be a substantial price reduction, if blindly reduce prices, good quality enterprises will be eliminated, the remaining will be those low limit feeding, or even shoddy enterprises." Over time, it is very easy to repeat the drug quality accident. "(Ma Jianzhong's)